Turkish Abstract Abstract Article PDF Similar Articles Mail to Author

Kudret Göz Hastanesi, Retina, Ankara, Uzm. Dr. Purpose: To compare the outcomes of intravitreal bevacizumab and intravitreal triamcinolone acetonide (TA) for the treatment of macular edema due to branch retinal vein occlusion (BRVO).
Materials and Methods: The records of patients with macular edema due to BRVO, treated with either intravitreal bevacizumab or intravitreal TA were retrospectively evaluated. The best corrected visual acuities recorded at 1st, 3rd and 6th months after the injection were compared with the initial visual acuity. Chi-square, paired samples t test and repeated measures ANOVA were used for statistical analysis.
Results: There were 22 patients (10 ischemic, 12 non-ischemic) in the bevacizumab group and 20 patients (10 ischemic, 10 non-ischemic) in the TA group. The difference between the initial visual acuity and the visual acuities at 1^st, 3^rd months after the intravitreal injection were significant in both groups (p<0.0001 for each). The difference between the initial visual acuity and the visual acuity at 6th month was significant in the TA group while it was similar in the bevacizumab group. The visual acuity gain was similar in both groups. The rate of intraocular complications was higher in the TA group.
Conclusion: Intravitreal bevacizumab and intravitreal TA are effective treatment modalities for macular edema due to BRVO. The visual acuity gain is similar. Intraocular complications are more common with TA. Keywords : Branch retinal vein occlusion, macular edema, bevacizumab, triamcinolone acetonide